Anti-Infective Drugs Market Overview
Anti-Infective Drugs Market Size is estimated to reach $131 billion by 2027. Furthermore, it is poised to grow at a CAGR of 4.3% over the forecast period of 2022-2027. An infection is the intrusion of disease-causing pathogens into an organism's bodily tissues, their multiplication, and the host tissues' reaction to the infectious organisms and the toxins they release. Anti-infectives are medicines that work to inhibit the spread or treat infections. Anti-infectives majorly include antibiotics, antivirals, antifungals, and antiparasitic medications that destroy or inhibit the growth of bacteria, harmful viruses, fungal cells, and parasitic agents respectively. Anti candida drugs are a type of antifungal drug that is used to treat candidiasis, which is a fungal infection caused by yeast. Patients with Acute Respiratory Infections or a common cold commonly use nonsteroidal anti-inflammatory drugs (NSAIDs) to relieve pain and fever. NSAIDs’ side effects vary depending on the drug, but most commonly include an increased risk of gastrointestinal ulcers and bleeding heart stroke, and kidney disease. The growing prevalence of infectious diseases, increase in health consciousness and healthcare expenditure as well as increasing awareness and adoption about Anti-Infective Drugs are some of the factors driving the Anti-Infective Drugs Market growth during the forecast period 2022-2027.
The report: “Anti-Infective Drugs Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Anti-Infective Drugs Market.
By Drug Type- Antibiotics, Antifungals, Antivirals, and others.
By Indication- HIV, Pneumonia, Tuberculosis, Respiratory Infections, Influenza and others.
By Route of Administration: Oral, Topical, and Parenteral.
By Distribution Channels- Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).
- Geographically, North America held a dominant market share in the year 2021 on account of healthcare infrastructure which is well developed, skilled healthcare professionals, and consumers with high buying power. Asia-Pacific is expected to offer lucrative growth opportunities to the manufacturers owing to the rising awareness about the effectiveness of Anti-infective drugs and increasing demand for better healthcare medications and facilities. The robust growth of the antivirals segment is predicted to augment the market growth during the forecast period of 2022-2027.
- An increasing geriatric population with a high risk of being susceptible to infectious diseases is estimated to drive the market growth of anti-infective drugs. The huge financial burden of R&D activities and the presence of substitutes in the market continues to pose threat to market growth.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Anti-Infective Drugs Market Report.
Anti-Infective Drugs Market: Market Share (%) by region, 2021
For more details on this report - Request for Sample
Anti-Infective Drugs Market Segmentation Analysis- By Drug Type
Anti-Infective Drugs Market based on drug type can be further segmented into Antibiotics, Antifungals, Antivirals, and others. Antiviral’s segment held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 4.6% over the forecast period of 2022-2027. Antiviral drugs are used to cure viral infections. Instead of killing their target pathogens, they inhibit their development. The increasing prevalence of HIV is one of the key factors driving the growth of the antivirals segment. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), there were approximately 37.7 million people across the globe with HIV in 2020. Antivirals work by preventing viruses from multiplying in the body, allowing the immune system to repair and prevent future damage. HIV can swiftly adapt and become resistant; a combination of HIV drugs is used. The global demand for antiviral drugs has risen substantially as a result of the COVID-19 epidemic. For instance, the FDA has approved the antiviral medication remdesivir for the treatment of COVID-19 in adults and children above 12 years. Rising investments in the development of antiviral drugs to treat covid and the increasing prevalence of other infectious diseases are estimated to augment the market growth over the forecast period.
Anti-Infective Drugs Market Segmentation Analysis- By Distribution Channels
Anti-Infective Drugs Market based on distribution channels type can be further segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Hospital Pharmacies held a dominant market share in the year 2021 primarily owing to the increase in the number of people being hospitalized due to infectious diseases and rising demand for these drugs by medical professionals to treat the patients in a better way. The pandemic augmented the number of people who needed to be hospitalized. Governments in various countries are partnering with hospitals to increase the rate at which antiviral drugs are distributed to those who need them. For instance, Tamil Nadu (India) government, partnered up with private hospitals to provide anti-viral drug Remdesivir during the pandemic.
However, Online Pharmacies are estimated to be the fastest-growing, with a CAGR of 4.9% over the forecast period of 2022-2027 on account of lockdown restrictions owing to the pandemic and increasing use of the internet as well as smart gadgets. The expansion of the online pharmacies market is expected to be aided by the increasing global penetration of e-commerce. It is estimated that there were 2.14 billion worldwide digital buyers, and by 2040, 95 percent of all purchases will be made through eCommerce, propelling the rise of online pharmacies.
Anti-Infective Drugs Market Segmentation Analysis- By Geography
The Anti-Infective Drugs market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 41% in the year 2021 as compared to the other counterparts on account of well-developed healthcare infrastructure, increasing prevalence of infectious diseases, and higher purchasing power of the consumers. According to statistics given by the Canadian government, influenza and pneumonia are among the top 10 leading causes of death in the country. It is estimated that each year influenza causes approximately 12,200 hospitalizations and 3,500 fatalities in Canada.
However, Asia-Pacific is estimated to be the fastest-growing, with a CAGR of 5.4% over the forecast period of 2022-2027 on account of the increase in demand for better healthcare facilities, the rising awareness about the effectiveness of anti-infective drugs, and increased vulnerability to infectious diseases owing to the rising geriatric population. According to the United Nations Population Fund (UNFPA), in Asia and the Pacific, one in every four persons will be over 60 years old by 2050 in Asia and the Pacific. Between 2010 and 2050, the region's population of older people (those over 60) will triple, reaching about 1.3 billion individuals. Increased investments and developments in the pharmaceutical industry by both government and private players are estimated to augment the market growth during the forecast period.
Anti-Infective Drugs Market Drivers
The Increasing Prevalence of HIV and other infectious diseases have benefitted the consumption of anti-infective drugs
The human immunodeficiency virus (HIV) attacks the immune system, making people more vulnerable to infections. Acquired Immunodeficiency Syndrome (AIDS) can develop if HIV is not treated timely. According to The Joint United Nations Program on HIV/AIDS (UNAIDS), around1.5 a million individuals worldwide acquired HIV in 2020 alone. CD4 cells, which are also known as white blood cells, are damaged or destroyed by HIV. The body's ability to combat illness is hampered as a result of this. Antiviral drugs stop the virus from growing, which lowers the amount of HIV in the body and the immune system starts producing the cells again.
The increase in the prevalence of influenza is another key factor driving the market growth. Influenza is a communicable virus that can cause mild to moderate symptoms as well as severe complications, including death. According to the Centres for Disease Control and Prevention (CDC), 35.5 million persons were infected by influenza in 2018–2019, resulting in 490,600 hospitalizations and 34,200 fatalities, thereby augmenting the Anti-Infective Drugs Industry growth.
Increasing the Geriatric Population with a higher risk of being susceptible to infectious diseases is driving the market growth.
According to estimates of the World Health Organisation (WHO), by 2030, one in every six persons in the world will be 60 years old or more, and by 2050, the world population of people aged 60 years and older will get doubled (2.1 billion). Between 2020 and 2050, the number of people aged 80 and more is predicted to triple, reaching 426 million. The human immune system weakens with age, making it less effective at fighting illnesses and less responsive to vaccinations. The immune system's ability to distinguish self from foreign antigens deteriorates. T cells that remember antigens they've previously encountered become slower at responding to new antigens. People are more susceptible to infections as a result of a combination of increased comorbid diseases and decreased immune system activity, driving the market growth.
Anti-Infective Drugs Market Challenges
Huge Investment Costs in R&D activities of the anti-infective drugs are impeding the market growth.
Costs for discovering and testing new drugs, creating incremental innovations such as product expansions, and clinical testing for safety monitoring or marketing objectives are all included in drug manufacturers' R&D expenditures. Drug development is a time-consuming and uncertain process, and many potential drugs never reach the market due to complex approval processes. Increased AMR and a lack of investment in expensive last-stage R&D operations aimed to tackle it continue to pose a threat to market growth. AMR is when bacteria, viruses, fungi, and parasites develop over time and stop responding to medications, infections become more difficult to treat, and the risk of transmission of infection, severe illness, and death increases. According to the UN, AMR causes 700,000 fatalities each year, with that number expected to rise to 10 million by 2050 if no solutions are discovered, posing a threat to market growth.
Anti-Infective Drugs Industry Outlook
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Anti-Infective Drugs Market. The top 10- Anti-Infective Drugs Market companies include:
- Novartis AG
- Merck & Co., Inc
- Alcon Pharmaceuticals Ltd
- Quest Diagnostics Inc.
- AstraZeneca Plc
- Anofi SA
- Gilead Sciences
- Novartis AG
- In August 2021, Xellia Pharmaceuticals, a pharmaceutical company specializing in anti-infective treatments, expanded its production capacity in Ohio. They released the first anti-infectives manufactured at the site for distribution to US hospitals.
- In April 2021, Pfizer, a multinational pharmaceutical and biotechnology corporation, acquired Amplyx Pharmaceuticals, Inc., a company that develops therapies for debilitating and life-threatening diseases, and expanded its anti-infectives portfolio with the addition of Fosmanogepix, a novel antifungal Phase 2 candidate (APX001). Amplyx's early-stage portfolio, which includes antiviral (MAU868) and antifungal (APX2039) drugs, is now owned by Pfizer.
- In October 2019, Cipla, an Indian multinational pharmaceutical company acquired a novel and patented anti-infective product, Elores, from Venus Remedies Ltd, a research and development-driven global pharmaceutical company. Elores is indicated for the treatment of life-threatening infections caused by gram-negative bacteria.
Report Code: HCR 0217